Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection

The coronavirus disease 2019 (COVID-19) pandemic requires the continued development of safe, long-lasting, and efficacious vaccines for preventive responses to major outbreaks around the world, and especially in isolated and developing countries. To combat severe acute respiratory syndrome coronavir...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulton, Stephen, Poutou, Joanna, Martin, Nikolas T., Azad, Taha, Singaravelu, Ragunath, Crupi, Mathieu J.F., Jamieson, Taylor, He, Xiaohong, Marius, Ricardo, Petryk, Julia, Tanese de Souza, Christiano, Austin, Bradley, Taha, Zaid, Whelan, Jack, Khan, Sarwat T., Pelin, Adrian, Rezaei, Reza, Surendran, Abera, Tucker, Sarah, Brown, Emily E.F., Dave, Jaahnavi, Diallo, Jean-Simon, Auer, Rebecca, Angel, Jonathan B., Cameron, D. William, Cailhier, Jean-Francois, Lapointe, Réjean, Potts, Kyle, Mahoney, Douglas J., Bell, John C., Ilkow, Carolina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527104/
https://www.ncbi.nlm.nih.gov/pubmed/34687845
http://dx.doi.org/10.1016/j.ymthe.2021.10.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527104/
https://www.ncbi.nlm.nih.gov/pubmed/34687845
http://dx.doi.org/10.1016/j.ymthe.2021.10.008

Ejemplares similares